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1270Objective: The lung allocation scorewas initiated in May 2005 to allocate lungs on the basis of medical urgency
and posttransplant survival. However, the relationship between lung allocation score and candidate outcomes
remains poorly characterized. The purpose of this study was (1) to describe outcomes by lung allocation score
at the time of listing and (2) to estimate the net survival benefit of transplantation by lung allocation score.
Methods: The United Network for Organ Sharing provided de-identified patient-level data. Analysis included
lung transplant candidates aged 12 years or more and listed between May 4, 2005, and May 4, 2009 (n¼ 6082).
Candidates were stratified according to lung allocation score at listing into 7 groups: lung allocation score less
than 40, 40 to 49, 50 to 59, 60 to 69, 70 to 79, 80 to 89, and 90 or more. Outcomes of interest included the risk of
death on the waiting list and likelihood of transplantation. The net survival benefit of transplantation was defined
as actuarial median posttransplant graft survival minus actuarial median waiting list survival, where the outcome
of interest was death on the waiting list or posttransplant; candidates were censored at the time of transplant or
last follow-up.
Results: In the lowest-priority strata (eg,<40 and 40–49), less than 4% of candidates died on the waiting list
within 90 days of listing. The median net survival benefit was lowest in the lung allocation score less than 40
(0.7 years) and lung allocation score 90þ group (1.95 years) and highest in the 50 to 59 (3.44 years), 60 to
69 (3.49 years), and 70 to 79 (2.81 years) groups.
Conclusions: The mid-priority groups (eg, 50–59, 60–69, 70–79) seem to achieve the greatest survival benefit
from transplantation. Although low-priority candidates comprise the majority of transplant recipients, survival
benefit in this group seems to be less than in other groups given the low risk of death on the waiting list. As ex-
pected, both the time to transplant and survival on the waitlist are lower in the higher-priority strata (eg, 80–89
and 90þ). However, their net survival benefit was likewise relatively low as a result of their poor posttransplant
survival. (J Thorac Cardiovasc Surg 2011;141:1270-7)The disparity between potential recipients and available do-
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The Journal of Thoracic and Cardiovascular SurServices published the ‘‘Final Rule,’’ which required that
all organ allocation systems place less emphasis on
waiting time and more on medical urgency.4 In response
to the ‘‘Final Rule,’’ the organ procurement and transplan-
tation network and the United Network for Organ Sharing
(UNOS) implemented the lung allocation score (LAS) in
May 2005. Under LAS, all lung transplant candidates are
prioritized according to LAS, which is calculated on the
basis of a multivariate model that is a weighted combination
of predicted waitlist and posttransplant survival at 1 year
(Appendix 1).1
Several studies, including those by our group, have
demonstrated favorable trends in waitlist times and wait-
list survival since the implementation of the LAS.5-7 An
increase in disease severity among listed patients has
also been observed.5,6,8,9 Despite this trend, acceptable
posttransplant survivals have been demonstrated in the
LAS era.5-7,10 However, as previously demonstrated, as
expected, posttransplant survival is inversely related to
LAS at the time of transplant.11,12
The objectives of this study were (1) to describe out-
comes by LAS at the time of listing and (2) to estimategery c May 2011
Abbreviations and Acronyms
LAS ¼ lung allocation score
LAS-L ¼ LAS at listing
LAS-T ¼ LAS at transplant
UNOS ¼ United Network for Organ Sharing
Russo et al Cardiothoracic Transplantationthe net survival benefit of transplantation by LAS score. It
has been suggested that a higher LAS score corresponds
not only to an earlier likelihood of transplantation but also
to a greater net transplant benefit.1,13,14 However, because
LAS weighs expected waiting list survival more heavily
than expected posttransplant survival, it is possible that an
increase in posttransplant morbidity and mortality may
result in less overall benefit. This may be especially true
at the highest LAS scores. To date, the relationship
between LAS and candidate outcomes remains poorly
characterized, and no studies have analyzed the overall
transplant benefit associated with various LAS ranges.
MATERIALS AND METHODS
Data Collection
Use of data in this analysis is consistent with the regulations of our uni-
versity’s institutional review board and the UNOS Data Use Agreement.
The Standard Transplant Analysis and Research Dataset were provided
by UNOS (data source 020909-3). The dataset contains information
collected from the UNetsm database forms, including the Transplant
Candidate Registration form, Transplant Recipient Registration form,
and Transplant Recipient Follow-up form. These data are the basis for
the UNOS Thoracic Registry.
Study Population
TheUNOSprovided de-identifiedpatient-level data for all lung transplant
candidates and recipients in the United States. Analysis included lung trans-
plant candidates aged 12 years or more and listed betweenMay 4, 2005, and
May 4, 2009 (n ¼ 6082). Follow-up data were provided through November
19, 2009. Patients were followed from the date of listing until death, trans-
plantation, or date of last known follow-up, and from the date of transplan-
tation until death, retransplantation, or date of last known follow-up, which
was the last day of follow-up data provided by UNOS. Recipients who
underwent simultaneous transplantation of another organ (n¼ 10) and those
with missing LAS data (n ¼ 53) were excluded from the analysis.TABLE 1. Lung allocation score strata
LAS
LAS at listing LAS at transplant
n % Mean SD n % Mean SD
<40 4796 69.9% 34.1 2.6 3251 68.4% 38.8 11.7
40–49 1260 18.4% 43.9 2.7 1002 21.1% 51.1 14.3
50–59 305 4.4% 54.2 2.9 224 4.7% 61.8 13.3
60–69 145 2.1% 64.3 2.9 99 2.1% 70.5 13.4
70–79 97 1.4% 74.8 2.9 63 1.3% 76.7 10.6
80–89 154 2.2% 85.8 3.1 69 1.5% 84.0 10.4
90þ 105 1.5% 92.2 1.4 47 1.0% 90.6 6.8
Total 6862 40.0 12.7 4755 45.3 17.1
LAS, Lung allocation score; SD, standard deviation. Shows mean LAS-L standard deviat
wait times.
The Journal of Thoracic and CarTo estimate survival on the waiting list across various ranges of LAS,
lung transplant candidates were stratified into 7 groups according to LAS
at listing (LAS-L): LAS-L less than 40, 40 to 49, 50 to 59, 60 to 69, 70
to 79, 80 to 89, and 90 or greater. To estimate posttransplant survival across
various ranges of LAS, lung transplant recipients were stratified into
7 groups according to LAS at transplant (LAS-T): LAS-T less than 40,
40 to 49, 50 to 59, 60 to 69, 70 to 79, 80 to 89, and 90 or greater. For
simplicity, candidates with LAS less than 40 and 40 to 49 were referred
to as ‘‘low-priority’’; candidates with LAS 50 to 59, 60 to 69, and 70 to
79 were referred to as ‘‘mid-priority’’; and candidates with LAS 80 to
89 and 90þwere referred to as ‘‘higher-priority.’’
Outcome Measures
Survival analysis. For waiting list survival, candidates were fol-
lowed from date of initial listing to death on the waiting list, transplant,
or last follow-up. The outcome of interest was death on the waiting list;
candidates were censored at the time of transplant or as lost/alive at last
known follow-up.
For posttransplant graft survival, recipients were followed from date of
transplant to graft failure (defined by patient death or retransplantation) or
last known follow-up. The outcome of interest was graft loss; candidates
were censored as lost/alive at last known follow-up. DLAS was defined
as LAS at the time of transplant minus LAS at the time of listing.
Net survival benefit of transplantation. Net survival benefit
was defined as actuarial posttransplant graft survival minus actuarial
survival on the waiting list at various time points (including 90 days
post-listing vs 90 days posttransplant, 1 year post-listing vs 1 year post-
transplant, and 2 years post-listing vs 2 years posttransplant).
The median net survival benefit of transplantation was defined as actu-
arial median posttransplant graft survival minus actuarial median survival
on the waiting list.
Data Analysis
All data were analyzed using the statistical software package Stata 9
(Stata Corp, College Station, Tex). Continuous variables were reported
as means, and categoric variables were reported as frequencies. Continu-
ous variables were compared with the Student t test, and categoric vari-
ables were compared with the chi-square test. All reported P values are
2-sided.
RESULTS
Patient Characteristics
LAS strata, including mean LAS-L standard deviation,
LAS-T  standard deviation (mean and median), DLAS
(mean and median), and wait times are summarized in
Table 1.DLAS Wait time (d)
Median Mean SD Median Mean SD Median
35.3 4.65 11.2 0.52 267.0 311.4 149.5
45.8 7.26 13.9 0.06 102.0 144.4 47.0
57.1 7.60 13.1 0.03 58.3 85.9 26.0
66.6 6.23 13.3 0.04 45.9 81.0 21.0
75.8 1.94 10.3 0.02 43.5 108.5 15.0
87.5 1.76 10.0 0.00 36.9 93.9 9.0
92.1 1.60 6.6 0.00 27.8 89.1 7.0
5.18 11.84 58.3 252.79
ion, LAS-T  standard deviation (mean and median), DLAS (mean and median), and
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FIGURE 1. Waitlist outcomes, including the percentage of candidates, stratified by LAS-L, who (A) died on thewaiting list, (B) underwent transplantation,
and (C) were alive on the waiting list as a function of the number of days accrued on the waiting list.
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Figure 1 summarizes waitlist outcomes, including the
percentage of candidates, stratified by LAS-L, who died
on the waiting list (A), underwent transplantation (B),
and were alive on the waiting list as a function of the num-
ber of days accrued on the waiting list (C). With the
exception of the LAS-L less than 40 group, few candidates
(1%–6%) were alive on the waiting list at 1 year. Candi-
dates were lost from the waiting list because of transplanta-
tion or death according to LAS-L score. Waitlist mortality
increased in a stepwise fashion for all LAS-L strata. At
1 year, 45% of candidates in the higher-priority strata
(80–89 and 90þ) underwent transplantation and 49%
were dead on the waiting list, whereas only 1% remained
alive on the waiting list. In the lower-priority strata (40–
49), at 1 year 77% of patients underwent transplantation
and 12% were dead on the waiting list, whereas only 6%
remained alive on the waiting list. In the lowest priority
stratum (<40), both waiting list mortality (7%) and trans-
plantation rates (60%) were the lowest, and as a result,
the number of candidates still alive on the waiting list
was the highest (26%). The middle-priority strata (50–
70) had the greatest proportion of candidates undergoing
transplantation.1272 The Journal of Thoracic and Cardiovascular SurNet Transplant Benefit
Figure 2 demonstrates median posttransplant survival
stratified by LAS-T, median waitlist survival by LAS-L,
and the median net survival benefit of transplantation by
LAS-T. The net survival benefit was lowest in the LAS
less than 40 (0.7 years) and LAS 90þ (1.95 years)
groups and highest in the 50 to 59 (3.44 years), 60 to 69
(3.49 years), and 70 to 79 (2.81 years) groups.
Figure 3 demonstrates that from listing to transplant there
was little movement between strata. The horizontal axis
represents strata at listing, and the bars represent LAS-T.
Figure 3 shows that 86.9% of candidates in the low-
priority group remained in the low-priority group at the
time of transplant. Likewise 75.7% of the medium-
priority group and 92.9% of the high-priority group re-
mained in their respective groups at transplant.
DISCUSSION
Before LAS, lung allocation was based on time accrued
on the waiting list.1-3 Although time on the waiting list
was intended to be a surrogate for disease severity, it
likely led to practices that had the opposite effect.
Patients were listed earlier in the course of their disease to
accrue more time, and those who made it to the top of thegery c May 2011
FIGURE 2. Median posttransplant survival stratified by LAS-T, median waitlist survival by LAS-L, and the median net survival benefit of transplantation
by LAS-T.
Russo et al Cardiothoracic Transplantationlist may have been healthy enough to wait longer.3,12,13
Conversely, the sickest patients, who had greater urgency,
may not have been listed because of the perception that
they would have little chance of surviving the wait for
a donor organ.5 The goal of the LAS is to eliminate these
potential biases and further maximize transplant benefit
per organ by simultaneously minimizing waitlist mortality
while maximizing posttransplant survival. The LAS uses
a variety of clinical factors determined from multivariableFIGURE 3. LAS at transp
The Journal of Thoracic and Carmodeling to estimate a patient’s likelihood of survival at
1 year on the waitlist and posttransplant.1
When the LASwas first introduced, critics expressed con-
cern that because LAS placed greater weight to expected
waitlist survival than posttransplant survival, this system
may compromise posttransplant outcomes by preferentially
allocating organs to more critically ill patients. Subse-
quently, however, a number of studies have demonstrated
no adverse effects on waitlist time and mortality5-8lant by LAS at listing.
diovascular Surgery c Volume 141, Number 5 1273
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acuity of transplant recipients.5,6,8 Nevertheless, in sub-
group analysis, recipients with higher LAS scores were
shown to have higher rates of postoperative complications,
lengths of stay, and posttransplant short- and long-term
mortality.7,10,11 These studies analyzed posttransplant
survival, but no studies have estimated the net benefit of
transplantation.
Outcomes on the Waiting List
The results of this current study demonstrate that LAS
score is associated with waitlist outcomes. The outcome
of interest (death on the waiting list or transplantation)
was determined in most candidates within the first year.
Among candidates with LAS-L 40þ, few (1%–6%) were
alive on the waiting list at 1 year. Also, among candidates
with LAS-L 60þ, less than 10% were alive on the waiting
list at 90 days. As expected, the proportion of patients
who died on the waiting list increased in a stepwise manner
as LAS-L increased. Although a relatively small proportion
of candidates in the lower LAS-L strata died within 1 year,
approximately one half of the high-priority candidates died
on the waiting list within 1 year.
The proportion of candidates undergoing transplantation
demonstrated a more complex relationship. The lower and
mid-priority groups demonstrated higher rates of trans-
plantation than the lowest or highest groups. In the highest
strata, the incidence of transplantation decreased because
waitlist mortality was high. In fact, a larger proportion
of candidates in the LAS-L less than 40 group underwent
transplantation than in the high-priority groups (eg, LAS-L
80–90 and 90þ).
Net Survival Benefit
This analysis further suggests that the lowest priority
(<40 and 40–49) and highest priority (80–90 and 90þ)
LAS groups had the lowest survival benefit. Surprisingly,
given the relatively low risk of death on thewaiting list, can-
didates with LAS less than 40 seem to have better survival
in the absence of transplantation, whereas candidates with
LAS 40 to 49 gain limited survival benefit from transplan-
tation. In the high-priority LAS groups (80–89 and 90þ),
a significantly higher percentage of patients were alive 1
year posttransplant compared with 1 year post-listing in
the absence of transplantation. Nevertheless, although sur-
vival on the waiting list in the absence of transplantation
is poor, posttransplant survival is also poor. Thus, although
LAS effectively ranks lung transplant candidates on the ba-
sis of degree of illness, the highest scores do not translate
into the greatest survival benefit. This discordance between
LAS score and survival benefit is likely due to the greater
weight of waitlist survival in the LAS algorithm.
It should be noted that estimates of survival on the wait-
ing list, and therefore the net survival benefit of transplanta-1274 The Journal of Thoracic and Cardiovascular Surtion, face limitations. This survival analysis assumes
candidates were censored randomly. However, this assump-
tion is not entirely true because this analysis censored can-
didates at the time of transplant, which is not a random
event. Under the LAS, sicker patients receive preference
in organ allocation. Nevertheless, this limitation may not
significantly influence the findings presented here for 2
reasons. First, the LAS-T, for most recipients, was not sig-
nificantly different than LAS-L (Figure 3). Furthermore, in
the highest LAS groups, the median posttransplant survival
is so limited it has minimal impact on the calculated net sur-
vival. That is, given median posttransplant survival in the
90þgroup is 2 years, the calculated net benefit will be low
regardless of expected waitlist survival. Therefore, this
potential for confounding is unlikely to change the conclu-
sions of this analysis.
Implications
Findings from the current analysis have a number of im-
portant implications. First, although LAS was developed to
preferentially allocate organs to the highest priority candi-
dates, the majority of organs, approximately 9 of every
10, were allocated to lower-priority candidates. This is par-
ticularly troublesome given the findings from this analysis
that limited survival benefit is offered by low-priority can-
didates receiving transplants, and a significant proportion
of high-priority candidates with greater potential for benefit
die waiting for an organ. This analysis also raises questions
regarding the highest LAS group receiving transplants
given their poor posttransplant survival. Although short-
term survival (at 90 days and 1 year posttransplant) seems
to be improved with transplantation in this group, longer-
term survival seems to be limited.
In an effort to avoid inefficient allocation of scarce organs
and truly maximize the potential benefit from available or-
gans, additional modifications to the current allocation sys-
tem should be considered. First, further study is needed to
better understand why such a large number of organs are
allocated to lung transplant recipients in the low-priority
group, whereas a significant number of candidates in the
higher-priority groups die on the waitlist. This may
result from preferential allocation of organs to local, thus
relatively lower-priority, recipients. Second to prevent allo-
cation of organs to extremely high-risk candidates, modifi-
cation of the LAS calculation should be considered in an
effort to truly maximize net benefit from transplantation.
We do not believe that centers should be strictly prohibited
from performing transplantation in any specific candidate.
However, as we have discussed, we support modifications
to the LAS that give lower priority to candidates expected
to have a poor outcome and higher priority to candidates
likely to receive greater benefit.15 It is possible that this
may be accomplished by placing less emphasis on expected
waiting list survival and more on expected posttransplantgery c May 2011
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stratification score could be imposed to discourage candi-
dates with an expected posttransplant mortality exceeding
a predefined threshold from receiving a transplant, and
used to inactivate the candidates or decrease their LAS. An-
other strategy is to use an alternate listing system, which is
already in use in other organ types, including heart trans-
plantation. Under such a system, high-risk recipients are
only eligible for organs that are not accepted for another
candidate and will otherwise be discarded. Such a system
maximizes the transplant benefit of optimal organs, but
can run the risk of further diminishing outcomes by pairing
the sickest recipients with marginal organs.
Study Limitations
These data have several limitations. First, large patient
registries may often suffer from incompleteness in data
entry. Fields contained within this database, however,
were generally well populated with a 90% to 99% data en-
try rate for the majority of variables. Patients with missing
data were not included in the analysis; however, given the
large sample size, it is unlikely that these excluded patients
would have significantly altered the results. Second, despite
the fact that the UNOS reporting system provided defini-
tions for variables in data guidelines, there could be inaccur-
acies in individual center reporting to UNOS. However, the
major outcome variables in this study, such as LAS, waitlist
time, waitlist mortality, and number of transplant candi-
dates listed, are major variables used in patient and center
evaluation, and would thus likely receive careful attention
in reporting. Third, because the LAS was developed in
2005, these data should be considered short-term and will
require further analysis for assessment of longitudinal
trends. Additional follow-up is needed, including longer-
term outcomes, such as 3- and 5-year posttransplant
survival. Fourth, LAS and other strategies for predicting
posttransplant outcomes have been shown to be only mildly
predictive of posttransplant outcomes.16 Finally, this analy-
sis considers only survival benefit; it does not consider
quality of life or economic measures. Although the
UNOS provides functional status data on recipients post-
transplant, it is generally poorly populated, and there are
no longitudinal quality of life data on waiting list candi-
dates. Findings from this analysis highlight the importance
of these data, especially given the finding of limited sur-
vival benefit in the lower-priority strata. It is possible that
despite the limited survival benefit in some subgroups,
there may be a significant benefit in terms of quality-
adjusted life years. Therefore, a national effort should be
implemented to measure quality of life in candidates and
recipients alike. Furthermore, future studies should assess
candidates’ preferences, including their willingness to trade
long-term survival for improved quality of life. This may be
particularly relevant to candidates in the lower-priorityThe Journal of Thoracic and Carstrata who have longer survival on the waiting list, but
poor quality of life.CONCLUSIONS
Increasing LAS is associated with increasing likelihood
of death on the waiting list. With the exception of the
LAS less than 40 group, few candidates (1%–6%) were
alive on the waiting list at 1 year. Low-priority candidates
(eg,<40 and 40–49) comprise the majority of transplant
candidates and recipients. Net survival benefit in low-
priority candidates seems to be less than mid-priority
groups, given the low risk of waiting list death. Mid-
priority strata (eg, 50–59, 60–69, 70–79) seem to have
the highest rate of transplantation at 1 year (along with
40–49) and the greatest survival benefit from transplanta-
tion. In the high-priority strata (eg, 80–89 and 90þ), survival
on the waiting list is poor in the absence of transplant,
with few candidates (<10%) alive on the waiting list at
90 days. Net survival benefit in the high-priority strata
was also minimal as a result of their relatively poor post-
transplant survival. These findings suggest that additional
modifications to the current allocation system must be
considered.
The authors thank the UNOS for supplying data and Katarina
Anderson for assistance with our analysis.References
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APPENDIX 1.
Calculation of the LAS involves the following patient
characteristics: age, body mass index, diabetes, functional
status, forced vital capacity (% predicted), systolic pulmo-
nary artery pressure, pulmonary capillary wedge pressure,
oxygen requirement, 6-minute walk distance less than
150 ft, continuous mechanical ventilation, partial pressure
of CO2, diagnosis, and creatinine.
The derivation of the LAS algorithm is explained in fur-
ther detail at the following UNOS website: http://www.
unos.org/docs/lung_allocation_score.pdf.Discussion
DrMichael Smith (Phoeniz, Ariz). Your work addresses an im-
portant question given the ongoing difficult problems with scarcity
of resources in transplantation principle, that is, the donor organs
themselves and the economic constraints on health care in general,
particularly in the arena of lung transplantation. The University of
Washington group and others (eg, the group in The Netherlands)
recently showed that among other common solid-organ trans-
plants, lung transplantation has been demonstrated to be the
most expensive, and this is mainly because of the higher cost of
postrecovery care. Many have suggested that although lung trans-
plantation can substantially improve quality of life, it has limited
cost-effectiveness. As a reaction to the difficult economic environ-
ment that we face today, some payers, including the Medicaid sys-
tem of my home state of Arizona, have determined that given the
limited survival advantages and poor cost-effectiveness, they will
no longer cover lung transplantation for their insured lives over the
age of 21 years. Given that we knowwe are trying to do the greatest
good for our patients with limited resources, how do we as trans-
plant physicians and surgeons act as good stewards of these limited
resources so that we can continue to provide care to our patients?
That is just a philosophical question.
The LAS has been an important step in the right direction in al-
lowing us to direct these limited resources more appropriately
compared with the old system of directing them simply by time
on the waiting list. Work such as yours helps to identify continued
limitations in the current system andmay help to point out facets of
the system that perhaps can be improved.
Given your findings, I have just a couple other comments and
questions. Your findings seem to identify some important limita-
tions of the current LAS system. One is that in approximately
90% of cases, our resources are going to patients who we are
not offering a survival benefit to and those in the lowest priority
group are actually better off without transplant from a survival
standpoint. At the other end of the spectrum, in the higher-1276 The Journal of Thoracic and Cardiovascular Surpriority groups, the LAS seems to over-advantage, if you will,
the sickness of the patient over the likelihood of an improved
survival after transplantation. As you mentioned, more long-
term data need to assessed to be certain of some of these con-
clusions, but given what you have at the present time, what
changes to the current LAS system would you recommend to
address these problems at either end of the LAS stratification
groups?
Dr Russo. Those are great questions. First, this analysis is not
meant to represent a criticism of the LAS. The LAS is a great
step forward over the previous system, which was essentially
based on waiting time alone. But under the current LAS system,
issues remain. The system should be designed to maximize the
net benefit of transplant However, medical urgency is weighted
more heavily than posttransplant survival. Therefore, patients in
the highest priority groups are sickest at the time of transplant
and thus, as expected, have the worst posttransplant outcomes.
This may prevent our maximizing the benefits from available or-
gans. In the future, I would support exploring the equal weighting
of expected survival on the waiting list and posttransplant survival
in future iterations of LAS. Second, as you point out, approxi-
mately 90% of the patients receiving transplants had lower-priority
LAS scores (<50). Concurrently, there were approximately 350
patients in the higher-priority groups who died on the waiting
list over the study period. You have to wonder why we’re perform-
ing transplantations in patients in the lower-priority group when
there are patients in the higher-priority group who die on the wait-
ing list. It may be because those patients were not appropriate for
transplant or for the donors who are available during their listing
time. However, I do not think this is the primary explanation.
Dr Smith. In terms of your methods, you looked at graft sur-
vival rather than patient survival after transplantation, and that
begs the question to me, do you think that re-transplantation plays
a significant role in improving survival in the groups of patients re-
ceiving transplants or offered transplantation, and could this bias
your data against a survival benefit of transplantation in the end?
Dr Russo. Graft survival is the standard measure of survival in
our analysis. In our opinion, graft survival has a number of advan-
tages over patient survival. First, given the critical scarcity of
organs available for transplantation, further expanding the benefit
of transplantation is predicated on improving the use of organs
available for transplantation. Analysis focusing on graft survival
rather than patient survival better addresses this important issue.
Moreover, if recipients receive multiple transplants during the
study period, survival obtained after retransplantation may be dou-
ble counted. That is, patient survival for recipients undergoing
transplantation twice during the study period is the sum of survival
of the initial transplant plus the survival after the second trans-
plant; patient survival after the second transplant will also be
included in analysis as a second, distinct observation, and thus is
counted twice. Finally, using patient survival in regression analysis
significantly confounds the model by allowing for a bailout strat-
egy of retransplant and introduces greater confounding by leaving
factors unaccounted for in the model, including the timing of the
retransplant, recipient clinical status at the time of the repeat trans-
plant, and characteristics of the donor involved in the retransplant.
Dr Smith. In the big picture, we cannot ignore the improve-
ments in quality of life that are offered to many of thesegery c May 2011
Russo et al Cardiothoracic Transplantationpatients because many would argue that lung transplantation
does allow many of our patients to become productive econom-
ically, both socially and economically, for their families and so-
ciety at large. I know that quality of life is beyond the scope of
this article, but perhaps you could comment on the relative im-
portance in these different patient priority groups, especially in
the absence of a demonstrated survival benefit. Along these
lines, how much should we weight quality of life in comparison
with survival advantage as we go forward in trying to improve
the LAS system?
Dr Russo. This is an excellent question. UNOS is a great re-
source because there are comprehensive and longitudinal survival
data. In outcome research, we frequently say that death is the ulti-
mate end point. But it is increasingly being recognized that quality
of life may be equally or more important. I think this is certainly
the case here.
Although the UNOS provides functional status data on recipi-
ents posttransplant, it is generally poorly populated, and there
are no longitudinal quality of life data on waiting list candidates.
Findings from this analysis highlight the importance of these
data, especially given the finding of limited survival benefit in
the lower-priority strata. It is possible that despite the limited sur-
vival benefit in some subgroups, there may be a significant benefit
in terms of quality-adjusted life years.
Therefore, a national effort should begin to measure quality of
life in candidates and recipients alike. Furthermore, future studies
should assess candidates’ preferences, including their willingness
to trade long-term survival for improved quality of life. This may
be particularly relevant to candidates in the lower-priority strata
who have longer survival on the waiting list, but poor quality of
life.
As stated in the Presidential Address, we need to be the stewards
of this effort. Given payors’ increasing resistance to reimburse for
costly therapies, if we cannot demonstrate a benefit from the
therapies that we offer, going forward, we may not be allowed to
provide them.
Dr Michael Mulligan (Seattle, Wash). Congratulations on
changing your title from when it was submitted to when it wasThe Journal of Thoracic and Carpresented. I think the title as it reads is a bit misleading, and for
those of us who sit on the pulmonary council, it is scary because
the LAS offers no guidance as to who should not receive a trans-
plant. Our charge over the next several years is to try to help refine
that, with help from our European colleagues.
I want to invite you to opine about 2 potential issues. One is if
you are assuming that limited survival benefit and a difficult to
quantitate quality of life benefit from performing transplantation
in a candidate with LAS less than 40, what would you propose?
Broader regional sharing akin to what we do for heart transplants,
where it is local 1A and 1B, and then it is farmed out before you
come back to a local status 2? And the other is because we double
weight waitlist mortality in calculating the LAS, what should we
do when the LAS starts to crest over 80? Because it is not a self-
correcting program, what would you propose for providing wider
more general usable user-friendly guidance for who should not
undergo transplantation?
Dr Russo. Those are great questions. First in terms of the organ
allocation issue, this is a question that our group is interested in ex-
ploring. We have preliminary data on this, which I did not present
here. However, if you look at the patients who undergo transplan-
tation with LAS less than 40, not surprisingly most of those organs
are procured locally, whereas candidates with LAS greater than 80,
organs were much more likely to be procured regionally or nation-
ally. This raises questions about broader organ sharing because
there be minimal benefit in performing transplantation in the
lower-priority group; in fact, there may be a negative benefit,
and again we have patients in the higher-priority groups dying
on the waitlist. Therefore, my bias is that, yes, there should be
broader organ sharing. However, the first step is to establish why
low-priority candidates are undergoing transplantation at such
a high rate while higher-priority candidates are dying on the
waitlist.
Regarding your second question, and I agree it is an important
issue, how should weweighmedical urgency versus expected post-
transplant survival? I cannot prove this, but I think that more
heavily weighing medical urgency prevents us from maximizing
benefit.diovascular Surgery c Volume 141, Number 5 1277
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